首页>
外国专利>
Use of a controlled release losartan oral dosage form, to decrease the inter individual gap of standard deviation of maximum concentration of the losartan, independent of administration of losartan before or after the meals
Use of a controlled release losartan oral dosage form, to decrease the inter individual gap of standard deviation of maximum concentration of the losartan, independent of administration of losartan before or after the meals
Use of a oral dosage form (A) comprising a coating or a matrix containing losartan (I) and allowing controlled release of (I), before or after meals, to decrease the inter individual gap of standard deviation of maximum concentration of (I) (C max), which results in a low variability of effectiveness of (A), when compared to a dosage form with immediate release of (I). Independent claims are included for: (1) a modified release oral dosage form (A) of losartan (I), comprising micro-units (II) containing (I), where (II) has an average diameter of 50-1000 (preferably 150-500) mu m, and carboxylic acid metabolite of (I) (E3174) has a specific plasma profile (i.e. C18h(i)=C18h (preferably 2.0 C18h(i)=C18h=C max(i)/2), where C18h is the plasma concentration of E3174 after 18 hour of administering (A), C18h(i) is the plasma concentration of E3174 obtained after administering immediate release form, C max is the maximum plasma concentration of E3174 after the administration of (A) and C max(i) is the maximum plasma concentration of E3174 obtained after administering immediate release form); and (2) a micro particle.
展开▼
